[1] García D, González JA, Lavalle FJ, et al.Hepatogenous diabetes: Is it a neglected condition in chronic liver disease. World J Gastroenterol, 2016,22(10):2869. [2] 胡庆玲,黄亚雄,谢元林.肝源性糖尿病发病机制研究进展.实用肝脏病杂志,2016,19(3):377-380. [3] Lock G,Bertram M.Impending liver failure after chemoimmunotherapy induced reactivationof hepatitis B - successful treatment with entecavir. Dtsch Med Wochenschr,2012,137(23):1248-1250. [4] 陈邦涛,冯旭娇,宋少娟,等.恩替卡韦与拉米夫定联合阿德福韦酯治疗乙型肝炎肝硬化失代偿期患者48周疗效MaTA分析.实用肝脏病杂志,2016,19(3):305-309. [5] Nguyen N H, Trinh H N, Nguyen T T, et al.Safety and efficacy of entecavir in adefovir-experienced patients. J Gastroenterol Hepatol,2015,30(1):43-50. [6] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):Ⅴ-ⅩⅩⅢ. [7] Yanxiao C,Ruijuan X.Organic anion and cation transporters are possibly involved in renal excretion of entecavir in rats. Life Sci,2011,89(2):1-6. [8] Lee J, Kim H Y, Kim Y J, et al.Barcelona clinic liver cancer staging system and survival of untreated hepatocellular carcinoma in a hepatitis B virus endemic area. J Gastroenterol Hepatol,2015,30(4):696-705. [9] Orsi E, Grancini V, Menini S, et al.Hepatogenous diabetes: Is it time to separate it from type 2 diabetes. Liver Int, 2016,37(7):950-962. [10] Diana H,Alberto F.Resultados en la práctica clínica del tratamiento de la hepatitis crónica por virus B con tenofovir y entecavir. Infection,2016,20(3):123-129. [11] David V,Ian J.Custoutilidade do tenofovir comparado com entecavir no tratamento em primeira linha da hepatite B crónica. GE J Português de Gastrenterologia,2012,19(4):170-182. [12] Ye Z,Min Z.Meta-analysis on treatment of chronic hepatitis B with telbivudine and entecavir. Infection Int,2012,1(4):216-223. [13] 闫丽辉,王少真,付亚坤,等.非酒精性脂肪性肝病对糖尿病患者胰岛功能的影响.中华内科杂志,2015,54(3):197-200. [14] Idilman R, Gunsar F, Koruk M, et al.Longterm entecavir or tenofovir disoproxil fumarate therapy in treatment-naive chronic hepatitis B patients in the real-world setting. J Viral Hepat,2015,22(5):504-510. [15] Seto W K, Hui A J, Wong V W, et al.Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. Gut,2015,64(4):667. [16] Boglione L, De N A, Cusato J, et al.Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-naive patients with chronic hepatitis B. Int J Antimicrob Agents,2016,48(3):324-327. [17] 林小萍,侯卫平,陆军平,等.恩替卡韦联合微生态制剂对乙型肝炎肝硬化患者肝功能及预后的临床研究.实用医学杂志,2016,32(6):993-995. [18] Takao W,Yoshio T.Effects of longterm entecavir treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients. Hepatol Int,2016,10(2):320-327. [19] Xiaolin D,Qingling L.Dynamics of lamivudine-resistant hepatitis B virus strains in patients with entecavir rescue therapy. Virus Genes,2013,47(1):1-9. [20] Hong K,Dong P.Comparison between clevudine and entecavir treatment for antiviral naive patients with chronic hepatitis B. Liver Int,2010,30(6):834-840. [21] Holstein A,Hinze S.Clinical implications of hepatogenous diabetes in liver cirrhosis.J Gastroenterol Hepatol,2002,17(6):677-681. |